xCARE closes Series A from Chugin Capital Partners
What's the deal? Tokyo-based xCAREDealroom has a profile for this one. Try Dealroom → has closed a Series A round with investment from Chugin Capital PartnersDealroom has a profile for this one. Try Dealroom →, the venture arm of Japan's Chugin Financial Group. The funding came through Chugin's Infinity Fund No. 3, which targets startups. This follows a pre-Series A round in January 2024.
xCARE operates a specialist platform for the pharmaceutical and medical device industries. It matches companies — including drugmakers, device manufacturers, and biotech ventures — with expert contractors for development projects spanning regulatory affairs, clinical development, quality assurance, and business development.
The platform now has more than 2,000 registered experts, split evenly between Japan and overseas.
Why now? Medical product development requires highly specialised talent, but needs vary from project to project. Traditional options have been limited to full-time hiring or complete outsourcing — both costly and inflexible.
xCARE offers a third path: on-demand expert contractors who plug into a company's own operations, letting it retain know-how while staying agile. "Changing the industry's business customs" is the company's stated mission, according to chief executive Sho FukunagaDealroom has a profile for this one. Try Dealroom →. International demand is growing, and xCARE is developing AI-powered matching to speed up and sharpen its expert recommendations.
What could go wrong? The freelance-contractor model is well established in IT and other sectors, but medical development carries higher regulatory stakes. Ensuring quality, compliance, and confidentiality across a distributed expert network is harder when the work involves drug approvals or clinical trials.
Scaling internationally adds further complexity — different jurisdictions mean different rules. And xCARE, founded in January 2022, is still young; it will need to prove the model can sustain growth beyond early adopters.
The signal: xCARE is still classified as early stage on Dealroom, and Chugin Capital Partners — a regional-bank investment fund rather than a specialist life-sciences VC — is the named backer, underscoring how thin dedicated medtech venture funding remains in Japan. The repeat investment from pre-Series A to Series A suggests the platform's contractor model is gaining traction with pharma clients, but the absence of a sector-focused co-investor signals that xCARE has yet to draw the kind of specialist capital that could accelerate its planned global and AI expansion.
Read more: PR TIMES
